TABLE 1.
Summary of the MICs of glycopeptide and non-glycopeptide antibiotics against S. aureus RN4220 and S. pneumoniae R6, expressing or not expressing VanZ.
| MIC (μg/ml) | ATCC 29213 | RN4220 pRMC2 | RN4220 vanZTei | RN4220 vanZg | R6 | R6 ΔvanZ | R6 ΔvanZ:vanZ |
| VAN | 0.25 | 0.5 | 0.5 | 1 | 0.25 | 0.25 | 0.25 |
| TEI | 0.125 | 0.5 | 1 | 8 | 0.125 | 0.03125 | 0.125 |
| ORI | 0.125 | 0.125 | 0.125 | 0.25 | 0.0078 | 0.0039 | 0.0078 |
| DALB | 0.125 | 0.125 | 0.125 | 0.5 | 0.03125 | 0.0078 | 0.03125 |
| MA79 | 0.25 | 0.125 | 0.5 | 0.25 | 0.5 | 0.25 | 0.5 |
| ERJ390 | 0.125 | 0.0156 | 0.25 | 0.25 | 0.5 | 0.125 | 0.5 |
| SZZS-12 | 0.125 | 0.0156 | 0.0625 | 0.0156 | 0.5 | 0.125 | 0.5 |
| CARB | 0.25 | 0.25 | 0.25 | 0.25 | 0.0625 | 0.0625 | 0.0625 |
| GEN | 1 | 1 | 1 | 1 | 0.25 | 0.25 | 0.25 |
| ERY | 0.125 | 0.125 | 0.125 | 0.125 | 0.125 | 0.125 | 0.125 |
VAN, vancomycin; TEI, teicoplanin; ORI, oritavancin; DALB, dalbavancin; CARB, carbenicillin; GEN, gentamicin; ERY, erythromycin. MIC values demonstrating resistance to clinically accepted glycopeptide antibiotics, according to EUCAST (2019) clinical breakpoints, are marked in bold. MIC values of the experimental glycopeptide antibiotics that increased due to vanZ expression are underlined. Decreased MIC values against S. pneumoniae R6ΔvanZ in comparison to wild-type S. pneumoniae R6 are in italics.